Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.

Détails

ID Serval
serval:BIB_BA13918CB3F1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
Périodique
Anticancer Research
Auteur(s)
Buchegger F., Allal A.S., Roth A., Papazyan J.P., Dupertuis Y., Mirimanoff R.O., Gillet M., Pelegrin A., Mach J.P., Slosman D.O.
ISSN
0250-7005 (Print)
ISSN-L
0250-7005
Statut éditorial
Publié
Date de publication
2000
Volume
20
Numéro
3B
Pages
1889-1896
Langue
anglais
Résumé
BACKGROUND: A combination of radioimmunotherapy (RIT) and radiotherapy (RT) should allow one to increase the dose of radiation targeting a particular tumour without the concomitant increase of toxic side effects. This might be obtained if the dose limiting side effect of each individual radiation therapy concerned different organs.
METHODS: Six patients with limited liver metastatic disease from colorectal cancer were treated with 6.9 GBq (range 4.7 to 8.4 GBq) 131I-labelled anti-CEA MAb F(ab')2 fragments combined with 20 Gy RT to the liver. Both treatments were given in close association, according to timing schedules evaluated in animals that gave the best results.
RESULTS: Reversible bone marrow and liver toxicity was observed in 6 and 5 patients, respectively. Three patients who first received 20 Gy RT to the liver, showed a significant platelet drop upon completion of RT. Repeat computerized tomography (CT) after 2 months showed a minor response in 1 patient and stable disease in 3 patients.
CONCLUSION: The study shows potential ways of combining RIT and RT, suggesting that this combination is feasible for the treatment of liver metastases.
Mots-clé
Adult, Animals, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/pharmacokinetics, Bone Marrow Diseases/etiology, Carcinoembryonic Antigen/immunology, Colorectal Neoplasms/pathology, Combined Modality Therapy, Dose Fractionation, Drug Administration Schedule, Feasibility Studies, Female, Humans, Immunoglobulin Fab Fragments/adverse effects, Immunoglobulin Fab Fragments/therapeutic use, Iodine Radioisotopes/adverse effects, Iodine Radioisotopes/pharmacokinetics, Liver Diseases/etiology, Liver Function Tests, Liver Neoplasms/radiotherapy, Liver Neoplasms/secondary, Male, Mice, Mice, Nude, Middle Aged, Premedication, Radioimmunotherapy/adverse effects, Radiotherapy Dosage, Radiotherapy, High-Energy/adverse effects, Tissue Distribution, Treatment Outcome
Pubmed
Web of science
Création de la notice
24/01/2008 17:12
Dernière modification de la notice
20/08/2019 15:28
Données d'usage